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INTRODUCTION
PET (positron emission tomography) is a newly
developed clinical imaging modality with remarkable
accuracy for metabolic mapping of numerous ma-
lignancies. It is beginning to have significant impact
on the management of cancer patients at different
stages of their disease (1-8). PET provides functional
information in addition to the morphology obtained
with conventional imaging modalities. PET depends
on positrons colliding with negative electrons to
create two 511 keV photons emitted at 180 degrees
to each other. These simultaneous photons are de-
tected by paired detectors encircling the body. In
oncologic imaging using PET, 18F-labeled 2-fluoro-
2-deoxyglucose (FDG) has been a favoredmetabolic
tracer because of several advantages. FDG is an ana-
logue of glucose labeled with the short-lived positron
emitting isotope 18F with a half life of 110 min. It acts
very similarly to glucose and is transported into cells
and converted to 18F-FDG-6-phosphate by hexokinase.
After conversion to FDG-6-phosphate, it is not me-
tabolized further and accumulates within the cells.
Low membrane permeability to charged ions causes
its entrapment within the cell and glucose utilization
rates can be determined from FDG tissue concen-
tration. This metabolic trapping of FDG in the cell
constitutes the rationale for imaging the in vivo dis-
tribution of the tracer. FDG uptake in tumors is pro-
portional to the metabolic rate of viable tumor cells,
which have increased demand for glucose compared
to normal tissue. It is possible to image the whole
body in a single session, which increases the op-
portunity for finding unsuspected disease sites which
are not evident on routine CT or MRI. The oncologic
indications of FDG PET include the following ; di-
agnosis, initial staging, and restaging of non-small
cell lung cancer, colorectal cancer, Hodgkin and non-
Hodgkin lymphoma, esophageal cancer, melanoma,
head and neck cancer (excluding neoplasms of central
nervous system and thyroid gland), breast cancer and
characterization of solitary pulmonary nodules, which
are covered by Medicare in the USA. The following
diseases are recognized as appropriate indications in
Japan since April 2002 ; lung cancer, breast cancer,
colorectal cancer, pancreatic cancer, metastatic liver
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tumor, malignant lymphoma, head and neck cancer,
brain tumor, unknown primary cancer and mela-
noma. Hepatocellular carcinoma, gastric cancer, and
genitourinary neoplasms like prostate cancer are not
imaged as effectively with FDG but some studies
have been published (2, 6).
We are currently imaging over 900 PET studies
a year, and more than half of them consist of head
and neck cancer and lung cancer patients. Here we
describe the clinical utility of FDG PET, illustrated
with PET images of head and neck cancer and
lung cancer.
FDG PET studies
Patients preparation
Patients were instructed to fast for at least 4 hours
before injection of 18F-FDG (except for glucose-free
oral hydration). Blood glucose level was measured
before injection of the tracer. Patients were not stud-
ied if the blood glucose was greater than 150 mg/dl.
After injection of FDG, patients were kept lying com-
fortably. No urinary bladder catheterization was per-
formed. Some of the head and neck cancer patients
were sedated with 1 mg alprazolam, given orally 30
minutes before FDG injection. These patients rested
quietly un the supine position during uptake and were
asked to minimize muscular activity, including vo-
calization to minimize muscle uptake which can oc-
casionally result in false positive interpretaion.
PET scan
FDG was produced with a 17 meV Scandatronix
cyclotron in our PET Center. The injection dose was
between 10 and 20 mCi (370-740 MBq). The dose was
adjusted for patient body weight using the following
protocol is following ; 10 mCi for less than 80 kg, 12.5
mCi for 80-100 kg, 15.0 mCi for 100-120 kg and 17.0
mCi for120-140kg. PET scans were obtained using
a PET scanner (Siemens HR+, biograph) 90min after
injection of the tracer. We have recently begun to
use a Biograph (Siemens, CTI) system, which is a
hybrid PET/CT system, for oncologic imaging. An
essential part of the study with conventional PET
system is the transmission scan with 68 Ge rotating
rods for attenuation correction. In the PET/CT sys-
tem, transmission scanning with 68 Ge is not nec-
essary, since we use the CT data, which is obtained
along with the PET scan, for attenuation correction
and anatomic characterization. The range of the scan
depended on the patient’s disease, and most of the
studies were acquired from the level of the OM line
through the level of the umbilicus. The patient is po-
sitioned on the table in the supine position and is
scanned at 5-7 bed positions, 180 sec per position.
The total scanning time is approximately15-20min.
It takes somewhat more time when imaging the entire
body, from the top of the head to the toes, such as for
patients with melanoma or soft tissue tumors in the
lower extremities.
Data analysis
The data are reconstructedwith the systemcomputer
and displayed on a separate workstation monitor for
imaging evaluation. Orthogonal images are reviewed
with and without attenuation correction by physicians.
PET provides not only static views but also quantitative
data in the form of standardized uptake value (SUV).
This is an uptakemeasurement that provides ameans
of comparison of FDG uptake between different le-
sions. For this measurement, a region of interest
(ROI) was placed manually. SUV [=tissue concen-
tration (kBq/ml)/injected FDG dose (kBq)/body
weight (g)] was calculated for each ROI. The SUV
that is reported is usually the maximum SUV since
that value best reflects the most metabolically active
part of the tumor. Measurement of SUV requires
attenuation correction to avoid the apparent variability
in FDG uptake due to the differences in tumor depth
within the body. The administered dose, corrected
for residual activity in the syringe and tubing, was also
accurately determined and the dose was decay cor-
rected to the time of imaging.
Normal distribution of FDG (Fig.1)
FDG uptake depicts tissue glucosemetabolism and
there are several sites of normal physiologic accu-
mulation of FDG (9, 10). The brain, heart and urinary
tract are the most prominent sites of tracer accumu-
lation. The brain uses glucose as its primary substrate.
Consequently, accumulation is physiologically high
in the cortex, basal ganglia, thalamus, and cerebellum.
Brain tumors sometimes overlap these regions of
high physiological uptake, which can make image
interpretations difficult andmay lead to false negatives.
The myocardium uses free fatty acids as its primary
substrate, but also uses glucose as an alternate sub-
strate. Up to 4% of the injected dose can accumulate
within the myocardium depending on the relative
availability of free fatty acids versus glucose. With
a sufficiently long fast, the myocardial metabolism
shifts to fatty acids as a source of energy. The tracer
is filtered by the renal glomerulus and not reabsorbed,
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thus renal uptake is not related to glucosemetabolism.
Hydration should be encouraged to promote diuresis
and decrease activity in the renal collecting system
and bladder. In the absence of hydration, diuretics,
and urinary catheterization, FDG is present in the
bladder and, to varying degrees, in the renal pelvis
and urinary tract. Significant FDG in the urinary ex-
cretory route may interfere with identification of renal
or pelvic tumors. In the resting state, skeletal muscle
relies on fatty acid oxidative metabolism for energy,
and muscular uptake of FDG is negligible. After ex-
ercise, however, significant uptake is observed in skele-
tal muscles because glycolysis becomes the major
source of energy. Hyperventilation may induce uptake
in the diaphragm, and stress-related muscle uptake
is often observed in the cervical, trapezius, andparaspi-
nal muscles. Uptake in the tonsils and associated,
lymphoid tissue, salivary glands, and thyroidmay also
be seen as a normal variant. Intense thyroid uptake
is indicative of thyroiditis. FDG accumulates in la-
ryngeal muscles in proportion to contractile activ-
ity during vocalization, however, this uptake is nearly
always symmetric. Uptake in the alimentary tract,
from esophagus to rectum, is variable in distribu-
tion and intensity. A small area of focal FDG uptake
is frequently seen at the gastroesophageal junction,
probably related to reflux. The wall of the stomach
is sometimes seen. The normal colon and small in-
testine may demonstrate increased uptake, probably
due to smooth muscle activity, bacterial uptake, and
metabolically active mucosa. Uptake in the cecum
may be related to lymphoid tissue in this region. The
liver and spleen are almost always identified in the
abdomen. Uptake in the bone marrow is normally
mild to moderate in the vertebral bodies, pelvis, hips,
long bones and sternum. Patients undergoing treat-
ment with granulocyte-stimulating factor have diffuse,
intense uptake in the bonemarrow. The accumulation
of FDG can be affected by the blood glucose level
via competitive displacement of FDG by the circulat-
ing glucose. In type I diabetic patients, insulin is not
recommended and FDG PET should be performed
in the morning after an overnight fast. In typeⅡpa-
tients, insulin may be used to control glucose levels,
although it may cause muscle uptake of glucose, and
may result in diffusely increased muscle uptake. At
least one hour should elapse after administration of
regular insulin to minimize muscle uptake.
Head and Neck cancer (Fig.2)
FDG PET has been used for staging, restaging
and evaluation of response to treatment (chemother-
apy, radiation therapy, surgery or the combination)
(3-5). In patients with a neck mass and unknown pri-
mary, PET frequently is able to detect the primary site.
Most head and neck cancers consist of squamous
cell carcinomas of nasopharynx, oral cavity, and larynx.
Accurate pretherapy evaluation of the primary site,
nodal disease and distant metastases is critical to
determine the appropriate therapeutic approach and
prognosis. CT and MR imaging lack sensitivity and
specificity in evaluating regional lymph nodes, due
to their dependence on size criteria.
Lymph node stagingwith FDGPET ismore accurate
than with conventional imagingmodalities, with a sen-
sitivity and a specificity of up to 90% and 94%, respec-
tively, compared with CT values of up to 82% and 85%,
and MR imaging values of up to 88% and 79% (11-14).
Radiation therapy and surgery can significantly distort
the anatomic structures. This limits the ability of CT
and MR imaging todifferentiate post-therapeutic changes
from residual or recurrent disease. Accurate detection
of residual disease or early recurrence with FDGPET
allows earlier change of patient treatment. The sen-
Fig. 1. Normal distribution of FDG of 62 year old male. a)
Attenuation-corrected anterior projection image. FDG accumulates
in the brain, adenoid tonsil, larynx, liver, spleen, kidneys and ver-
tebral bodies. Some bowel uptake is also seen inferior to left kid-
ney. b) Sagittal image. Soft palate uptake is seen. c) Axial image
at mid lung level.
Fig. 2. Head and neck cancer patient of 42 year old male with
a squamous cell carcinoma of the right tonsil. a) Intense uptake
is present in the primary tumor of the right tonsil with metastatic
node. b) A nodal disease is obvious in the right neck with necrotic
part. c) Sagittal image of the primary tumor. Maximum SUVs of
primary tumor : 10.7, right neck node : 8.5
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sitivity of FDG PET in detecting residual or recurrent
disease at the primary site is comparable with those
of CT and MR imaging (88%-100% vs 70%-92%), but
its specificity is superior (75%-100% vs 50%-57%)(15-
17).
Early identification of response to chemotherapy
may help to improve survival in treatment of locally
advanced head and neck cancer. A greater reduction
between pre and post therapyFDGuptakemaypredict
a better remission (18). Chemotherapeutic regimens
may be changed earlier or additional surgery could be
performed earlier if nonresponders couldbe accurately
identified after their first chemotherapy.
The waiting period before doing FDG PET after
some treatment or procedure is now not well defined.
Our current recommendations are to wait 7 days after
needle biopsy, 2 weeks after chemotherapy, 4 weeks
after surgical resection, and 3 months after the com-
pletion of radiotherapy to avoid the false positive find-
ings that can occur due to post inflammatory changes
after the procedure. False negative results can occur
due to necrotic tumors and small tumors.
Lung cancer (Fig.3)
With the improvements in high resolutionCT(HRCT)
and multi-detector CT (MDCT), it is becoming more
common to detect pulmonary nodules. However, it
is frequently difficult to determine the benign vs. ma-
lignant status in the case of multiple nodules or tiny
nodules. There are no specific CT criteria that allow
reliable distinction of benign from malignant pulmo-
nary nodules. In a recent meta-analysis, FDG PET
was reported to have a sensitivity of 97% and a specific-
ity of 78% in characterizing solitary pulmonary nodules
(19). SUVs of more than 2.5 are considered very wor-
risome for cancer. In addition to initial staging, restag-
ing, and evaluation of response to therapy, evaluation
of solitary pulmonary nodules showing low uptake
with FDG PET allows patients to be followed upwith
sequential imaging rather than invasive procedures.
In initial staging of lung cancer, FDG PET has been
successfully used in mediastinal nodal staging with
a sensitivity of 93% and a specificity of 99% (20). At least
10% of patients are found to have unsuspectedmetas-
tatic disease at FDG PET when results of routine CT
are not definitive for metastasis. In addition, some false-
positive findings at CT, including adrenal nodules which
are often benign adenomas, are correctly interpreted
as negative with FDG PET (21). FDG PET can avoid
some invasive procedures by identifying distant or
more accessible sites in patients who are surgical can-
Fig. 3. Recurrent head and neck cancer patient, a 71 year old
male with squamous cell carcinoma of right piriform sinus after
surgery and radiation therapy. a) The local recurrence and left
neck disease are apparent. SUVs of local recurrence:14.5, neck
disease : 13.9. b) Right lung and left hilar metastases are also
displayed. SUVs of right lung metastasis : 2.2, left hilar node :
6.3. c) Axial view at the level of right lung metastasis. Another
lesion of left lung is seen. SUV of this lesion is 3.3.
Fig. 4. Lung cancer patient of 68 year old male with a non small
cell carcinoma of the right lung. Primary tumor, multiple nodal and
bone metastases are present. a) Primary tumor and bone mets.
b) Mediastinal, right supraclavicular and left neck nodal diseases.
c) Axial image. Maximum SUVs of primary tumor:11.5, mediastinal
lymph node : 13.9, left rib : 11.7, thoracic spine : 7.1, left neck
node : 7.4, right supraclavicular node : 13.6
Fig. 5. Lung cancer patient, a 44 year old female with poorly
differentiated adenocarcinoma of the left upper lobewith bone and
liver metastases. a) Primary tumor (SUV=9.3), and right iliac bone
metastasis (SUV=7.9). The intense uptake in the center of the pelvis
corresponds to bladder. b) Posterior view of image a). Left hilar
(SUV=9.6) and subcarinal (SUV=5.6) lymphnodes are demonstrated.
The metastatic liver tumor in the lower posterior segment (SUV=
7.7) is also seen (arrow). c) Another liver lesion in middle lobe
(SUV=12.3). This patient had two liver metastasis.
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didates but are found to have unresectable tumors.
Accordingly, treatment is altered in up to 41% of cases
on the basis of the FDG PET findings (22, 23).
Postsurgical anatomical distortionmakes it difficult
to distinguish residual or recurrent disease from post-
operative fibrosis with routine follow upCT. Equivocal
findings suggestive of tumor recurrence or residual
disease can be accurately characterized with FDG
PET. FDG PET can identify changes in glucose me-
tabolism after treatment and may be a better indicator
of a favorable response to therapy than the decrease
in tumor size determined with CT (24). It has been
suggested that a relative decrease in FDG uptake
may only indicate a partial response due to destruction
of cells sensitive to the therapy and while other resis-
tant cells continue to be viable. It may be important
to evaluate the magnitude of the decline in uptake
of SUV. The larger decline of SUV is considered as
a better response to therapy.
There are some pitfalls that may result in false-
positive or negative findings. Granulomatous disease
such as sarcoidosis, tuberculosis, histoplasmosis, as-
pergillosis, mycobacterium avium-intracellulare, coc-
cidiomycosis, and other infectious processes, such
as pneumonia, may result in false-positive findings.
Malignant tumors with low glucosemetabolism such
as bronchioloalveolar carcinoma can give rise to false-
negative results. Well-differentiated adenocarcinomas
have relatively less intense FDG accumulation, par-
ticularly lesions smaller than 1.0 cm in diameter.
CONCLUSION
We have described the clinical utility of FDG PET.
PET is a noninvasive diagnostic technique that allows
identification of biochemical and physiologic altera-
tions in tumors. FDGPET isbecomingwidely accepted
in the initial staging of cancer, management of recur-
rent disease, and therapy monitoring. FDG PET and
anatomic imagingmodalities, such as CT orMRI, play
complementary roles in allowing amore accurate over-
all evaluation of cancermanagement.Moreover, newly
developed hybrid PET/CT systems should be a more
powerful tool. In conclusion, the role of PET in tumor
imaging will continue to increase as more indications
are approved and newer tumor-specific tracers are
developed.
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